Therefore, pre-clinical study in animal models of cervical cancer should be carried out through tumor-targeted delivery of anti-PLCG2 or CALM1 siRNA in combination with passively diffusible anti-cancer drugs. This evidence concerns the gene PLCG2 and cervical cancer.